GlassScriptPhysician profile
Ariyo Olobatoke
NPI 1184890584
$12,349.02
in general payments reported to CMS, 2019-2025
27 companies · $4,869 in 2025
The $4,869 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,040 · 2020: $747 · 2021: $146 · 2022: $2,186 · 2023: $400 · 2024: $1,960 · 2025: $4,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $1,700 · Food and Beverage: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $1,700.13 |
| Food and Beverage | $1,529.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,099.62 | 2022-2025 | |
| Ekos Corporation | $1,148.13 | 2019 | |
| Covidien LP | $546.28 | 2020 | |
| Glaxosmithkline, LLC. | $538.68 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Cook Incorporated | $500.47 | 2024 | Blue Rhino |
| Astrazeneca Pharmaceuticals LP | $493.73 | 2021-2024 | Breztri, Airsupra, Fasenra |
| Cook Medical LLC | $272.87 | 2024 | Blue Rhino |
| Actelion Pharmaceuticals US, INC. | $216.83 | 2019-2020 | |
| Abiomed | $208.31 | 2023-2024 | Impella |
| Noah Medical Corporation | $174.91 | 2024 | Galaxy |
| Janssen Pharmaceuticals, INC | $173.93 | 2019-2020 | |
| Insmed, INC. | $170.72 | 2019-2025 | Arikayce |
| United Therapeutics Corporation | $132.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.70 | 2019-2024 | Ofev |
| Mallinckrodt Enterprises LLC | $115.53 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $92.10 | 2019 | |
| Medtronic, INC. | $87.73 | 2023 | Illumisite |
| Csl Behring | $50.88 | 2019 | |
| Scpharmaceuticals INC. | $43.08 | 2025 | |
| Grifols USA, LLC | $26.63 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $24.80 | 2023 | Zerbaxa, Dificid |
| Pulmonx Corporation | $23.40 | 2020 | |
| Amgen INC. | $16.51 | 2025 | Tezspire |
| Resmed Corp | $15.55 | 2022 | |
| Olympus America INC. | $15.42 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $15.23 | 2022 | |
| Janssen Biotech, INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariyo Olobatoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.